Evidence map›Paper›PMID 35227280›Full record

ReviewChinese medicine2022

Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review.

Xiaomin Kang, De Jin, Linlin Jiang, Yuqing Zhang, Yuehong Zhang, Xuedong An, Liyun Duan, Cunqing Yang, Rongrong Zhou, Yingying Duan and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chinese medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Novel inhibition ofApplied and environmental microbiology · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Inhibitory effect of Jingfang mixture on Staphylococcus aureus α-hemolysin.World journal of microbiology & biotechnology · 2024
    Article
  16. Pathogenic mechanisms of cardiovascular damage in COVID-19.Molecular medicine (Cambridge, Mass.) · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaomin Kang *Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.ORCID http://orcid.org/0000-0002-3002-3786
De Jin *Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Linlin JiangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yuqing ZhangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yuehong ZhangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xuedong AnGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liyun DuanGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Cunqing YangGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Rongrong ZhouGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yingying DuanGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yuting SunGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Fengmei LianGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. 694397644@qq.com.

Funding

State Administration of Traditional Chinese Medicine of the People's Republic of China 2020ZYLCYJ04-1
6 · The paper itself

Abstract

Since the outbreak of coronavirus disease 2019 (COVID-19), traditional Chinese medicine (TCM) has made an important contribution to the prevention and control of the epidemic. This review aimed to evaluate the efficacy and explore the mechanisms of TCM for COVID-19. We systematically searched 7 databases from their inception up to July 21, 2021, to distinguish randomized controlled trials (RCTs), cohort studies (CSs), and case-control studies (CCSs) of TCM for COVID-19. Two reviewers independently completed the screening of literature, extraction of data, and quality assessment of included studies. Meta-analysis was performed using Review Manager 5.4 software. Eventually, 29 RCTs involving 3060 patients and 28 retrospective studies (RSs) involving 12,460 patients were included. The meta-analysis demonstrated that TCM could decrease the proportion of patients progressing to severe cases by 55% and the mortality rate of severe or critical patients by 49%. Moreover, TCM could relieve clinical symptoms, curtail the length of hospital stay, improve laboratory indicators, and so on. In addition, we consulted the literature and obtained 149 components of Chinese medicinal herbs that could stably bind to antiviral targets or anti-inflammatory or immune-regulating targets by the prediction of molecular docking. It suggested that the mechanisms involved anti-virus, anti-inflammation, and regulation of immunity. Our study made a systematic review on the efficacy of TCM for COVID-19 and discussed the possible mechanisms, which provided clinical reference and theoretical basis for further research on the mechanism of TCM for COVID-19.

Indexed as

Coronavirus disease 2019COVID-19EfficacyMechanismSystematic reviewTraditional Chinese medicine

Identifiers

PMID35227280
PMCPMC8883015

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.